Standardised Ki‐67 proliferation index assessment in early‐stage laryngeal squamous cell carcinoma in relation to local control and survival after primary radiotherapy

Ambiguous results have been reported on the predictive value of the Ki‐67 proliferation index (Ki‐67 PI) regarding local control (LC) and survival after primary radiotherapy (RT) in early‐stage laryngeal squamous cell cancer (LSCC). Small study size, heterogenic inclusion, variations in immunostaining and cut‐off values are attributing factors. Our aim was to elucidate the predictive value of the Ki‐67 PI for LC and disease‐specific survival (DSS) using a well‐defined series of T1‐T2 LSCC, standardised automatic immunostaining and digital image analysis (DIA).

[1]  Bert van der Vegt,et al.  Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement , 2018, Breast Cancer Research and Treatment.

[2]  J. Roodenburg,et al.  Phosphorylated FADD is not prognostic for local control in T1‐T2 supraglottic laryngeal carcinoma treated with radiotherapy , 2017, The Laryngoscope.

[3]  E. Ioachim,et al.  Biomarkers of head and neck cancer, tools or a gordian knot? , 2015, International journal of clinical and experimental medicine.

[4]  T. Carey,et al.  HIF‐1α and CA‐IX as predictors of locoregional control for determining the optimal treatment modality for early‐stage laryngeal carcinoma , 2015, Head & neck.

[5]  Johan Bussink,et al.  Prognostic value of the proliferation marker Ki‐67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial , 2015, Head & neck.

[6]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[7]  E. Schuuring,et al.  Prognostic significance of HIF‐1a, CA‐IX, and OPN in T1–T2 laryngeal carcinoma treated with radiotherapy , 2013, The Laryngoscope.

[8]  K. Fung,et al.  Ki-67 expression predicts radiotherapy failure in early glottic cancer. , 2012, Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale.

[9]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[10]  F. Hoebers,et al.  Radiotherapy in laryngeal carcinoma: Can a panel of 13 markers predict response? , 2009, The Laryngoscope.

[11]  T. Helliwell,et al.  Expression of cell cycle associated proteins influences radiocurability of T2N0 squamous cell carcinoma of the larynx. , 2008, Oral oncology.

[12]  E. Schuuring,et al.  Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[13]  C Caldas,et al.  Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. , 2008, Breast.

[14]  Y. Horibe,et al.  Ki-67, p53 and epidermal growth factor receptor expression in early glottic cancer involving the anterior commissure treated with radiotherapy. , 2008, Auris, nasus, larynx.

[15]  M. Papotti,et al.  Cell Membrane Reactivity of MIB-1 Antibody to Ki67 in Human Tumors: Fact or Artifact? , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[16]  M. Casparie,et al.  Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[17]  B. Haffty,et al.  Tissue Microarray Analysis Reveals Prognostic Significance of COX‐2 Expression for Local Relapse in T1–2N0 Larynx Cancer Treated with Primary Radiation Therapy , 2004, The Laryngoscope.

[18]  S. Ell,et al.  Overexpression of Bcl‐2 in squamous cell carcinoma of the larynx: A marker of radioresistance , 2002, International journal of cancer.

[19]  P. Bradley,et al.  MIB-1 and p53 expression in radiotherapy-resistant T1aN0M0 glottic squamous cell carcinoma. , 2001, Clinical otolaryngology and allied sciences.

[20]  C. Terhaard,et al.  Ki‐67 and p53 in T2 laryngeal cancer , 1998, The Laryngoscope.

[21]  P. V. van Diest,et al.  Proliferation markers in tumours: interpretation and clinical value. , 1998, Journal of clinical pathology.

[22]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[23]  M. Hareyama,et al.  Accelerated radiotherapy for T1, 2 glottic carcinoma: analysis of results with KI-67 index. , 2000, International journal of radiation oncology, biology, physics.